Trodelvy Receives New Indication for Advanced Urothelial Cancer

Web Exclusives - FDA Approvals, Select Drug Profiles

On April 13, 2021, the FDA accelerated the approval of sacituzumab govitecan (Trodelvy; Immunomedics), a Trop-2 antibody and topoisomerase inhibitor, for patients with locally advanced or metastatic urothelial cancer who had received a platinum-containing chemotherapy and either a PD-1 or a PD-L1 inhibitor. The FDA had granted sacituzumab govitecan a breakthrough therapy designation for this indication.

A week earlier, on April 7, 2021, the FDA granted sacituzumab govitecan regular approval for the treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received ≥2 systemic therapies, at least 1 for metastatic disease. Sacituzumab govitecan was granted an accelerated approval for TNBC in April 2020.

The FDA approval of the new indication for sacituzumab govitecan for the treatment of advanced urothelial cancer was based on results of the TROPHY study, a single-arm, multicenter clinical trial of 112 patients with locally advanced or metastatic urothelial cancer who had received a platinum-containing chemotherapy and either a PD-1 or a PD-L1 inhibitor. Patients received sacituzumab govitecan, 10 mg/kg intravenously, on days 1 and 8 of a 21-day treatment cycle.

The main efficacy measures were the objective response rate (ORR) and the duration of response. The confirmed ORR was 27.7% (95% confidence interval [CI], 19.6-36.9), including 5.4% complete responses and 22.3% partial responses. The median duration of response was 7.2 months (95% CI, 4.7-8.6).

The most common (>25%) adverse reactions reported with sacituzumab govitecan were neutropenia, nausea, diarrhea, fatigue, alopecia, anemia, vomiting, constipation, decreased appetite, rash, and abdominal pain.

Continued approval of this indication may be contingent on the demonstration of a clinical benefit in a confirmatory clinical trial.

Related Items
Yescarta First CAR T-Cell Therapy FDA Approved for Large B-Cell Lymphoma
Web Exclusives published on July 29, 2022 in FDA Approvals
Tibsovo Received a New Indication, in Combination with Azacitidine, for Newly Diagnosed Patients with AML and IDH1 Mutation
Web Exclusives published on July 22, 2022 in FDA Approvals
Kymriah Received Accelerated FDA Approval for Relapsed or Refractory Follicular Lymphoma
Web Exclusives published on July 19, 2022 in FDA Approvals
Vidaza Received New Indication for Patients with Newly Diagnosed Juvenile Myelomonocytic Leukemia
Web Exclusives published on July 19, 2022 in FDA Approvals
Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC
Web Exclusives published on May 26, 2022 in FDA Approvals
Last modified: August 30, 2021
Copyright © Engage Healthcare Communications, LLC. All rights reserved.